These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30609400)

  • 1. Venetolax with Azacitidine Drains Fuel from AML Stem Cells.
    Nakada D
    Cell Stem Cell; 2019 Jan; 24(1):7-8. PubMed ID: 30609400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
    Pollyea DA; Stevens BM; Jones CL; Winters A; Pei S; Minhajuddin M; D'Alessandro A; Culp-Hill R; Riemondy KA; Gillen AE; Hesselberth JR; Abbott D; Schatz D; Gutman JA; Purev E; Smith C; Jordan CT
    Nat Med; 2018 Dec; 24(12):1859-1866. PubMed ID: 30420752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
    Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
    Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 7. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 8. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
    Abbott D; Cherry E; Amaya M; McMahon C; Schwartz M; Winters A; Schowinsky J; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Leuk Lymphoma; 2021 Jun; 62(6):1466-1473. PubMed ID: 33375853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
    Ivanov V; Yeh SP; Mayer J; Saini L; Unal A; Boyiadzis M; Hoffman DM; Kang K; Addo SN; Mendes WL; Fathi AT
    Future Oncol; 2022 Aug; 18(26):2879-2889. PubMed ID: 35852098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
    Perl AE; Vyas P
    Clin Cancer Res; 2022 Jul; 28(13):2719-2721. PubMed ID: 35452083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
    Islam N; Reuben JS; Dale J; Gutman J; McMahon CM; Amaya M; Goodman B; Toninato J; Gasparetto M; Stevens B; Pei S; Gillen A; Staggs S; Engel K; Davis S; Hull M; Burke E; Larchick L; Zane R; Weller G; Jordan C; Smith C
    JCO Clin Cancer Inform; 2022 Sep; 6():e2200030. PubMed ID: 36194842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
    Yasu T; Gando Y; Shirota M; Kosugi N; Kobayashi M
    Leuk Lymphoma; 2024 Jan; 65(1):128-131. PubMed ID: 37797220
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
    Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
    Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 16. Changing trends in the therapy of acute myeloid leukemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101333. PubMed ID: 34865705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
    Liu XH; Wu Y; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):166. PubMed ID: 35381683
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
    Chojecki AL; Arnall J; Boselli D; Patel R; Chiad Z; DiSogra KY; Karabinos A; Chen T; Cruz A; Verbyla A; Ai J; Knight TG; Ragon BK; Shah NA; Sanikommu SR; Symanowski J; Avalos BR; Copelan EA; Grunwald MR
    Leuk Res; 2022 Aug; 119():106904. PubMed ID: 35753088
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
    Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
    Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
    [No Abstract]   [Full Text] [Related]  

  • 20. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
    Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
    Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.